Some links on this page are affiliate links. DrawDose may earn a commission on signups through these links at no additional cost to you. The selections below are based on regulatory framework and operational stability, not commission rates. We don't link to vendors we wouldn't recommend.
DrawDose is a research-tool publisher. We don't sell peptides, dispense medications, or operate as a healthcare provider. The reconstitution math on this site applies whether your peptide came from a licensed pharmacy, a compounding clinic, or a research supplier. The access channels themselves matter though, and the honest answer for where to legally access each peptide DrawDose covers depends on which peptide and what you're doing with it.
This page covers three channels: branded FDA-approved drugs through licensed telehealth, compounded peptides through 503A and 503B telehealth clinics, and standard injection supplies. We don't list research peptide vendors. The reason is below.
The regulatory framework in two paragraphs
Per the FDA's published guidance, peptide products in the US fall into one of three categories. FDA-approved drugs (Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus) are dispensed by licensed pharmacies with prescriptions and have undergone clinical trials, label review, and post-market surveillance. Compounded drugs are prepared by 503A pharmacies (patient-specific prescriptions) or 503B outsourcing facilities (bulk under FDA oversight) using bulk drug substances that are FDA-approved, USP-monographed, or on the 503A bulks list. Research-grade chemicals are sold for in-vitro laboratory use only, are not FDA-approved, and per the FDA's March 2025 Final Guidance are presumed to be intended for human use when shipped to residential addresses regardless of label disclaimers.
The legal status of a given peptide depends on which category it falls into and what's happened to it recently. Tirzepatide and semaglutide are FDA-approved (Mounjaro/Zepbound, Ozempic/Wegovy/Rybelsus); compounding access ended after the FDA resolved the shortage in early 2025. BPC-157, TB-500, CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604, and selank are moving back to Category 1 of the 503A bulks list per the HHS reclassification announced in March 2026, with formal Federal Register publication expected through Q2-Q3 2026. The framework is shifting; we update this page when meaningful changes ship.
Branded FDA-approved drugs via licensed telehealth
Per the Hims/Novo Nordisk partnership announced March 9, 2026, Hims & Hers now distributes branded Novo Nordisk semaglutide products (Ozempic for type 2 diabetes, Wegovy for chronic weight management) through their telehealth platform. The intake includes a virtual consultation with a licensed provider, a prescription written by that provider when clinically appropriate, and dispensing through a licensed pharmacy. The product is the same FDA-approved drug as if it were prescribed by an endocrinologist and filled at Walgreens.
Per Ro's announced partnership with Eli Lilly, Ro distributes branded Zepbound (tirzepatide) for chronic weight management through the same model. The intake is a virtual consultation, a prescription when appropriate, and dispensing through licensed pharmacies.
For users with insurance coverage, the traditional pharmacy channel is often cheaper. Cost without insurance for branded GLP-1s runs $1,000 to $1,400 per month at retail pharmacies; with insurance and the manufacturer savings programs, copays can drop to $25 to $300. Telehealth platforms like Hims and Ro typically don't accept insurance for branded GLP-1s and charge cash prices that are competitive but not lower than insured retail. The trade-off is access speed (telehealth intake is often faster than booking with a primary care physician) and prescription continuity (telehealth platforms manage refills and titration follow-ups).
This channel is the most legally defensible path to FDA-approved GLP-1 medications. The drugs themselves have undergone clinical trials. The dispensing pharmacy is licensed. The prescription is written by a licensed provider. State attorneys general enforcement actions in 2025-2026 have specifically targeted distributors operating outside this framework; this is the inside.
Hims & Hers — branded Ozempic and Wegovy Ro — branded Zepbound
Compounded peptides via 503A and 503B telehealth clinics
Per the FDA's compounding framework, 503A pharmacies prepare patient-specific prescriptions under state pharmacy board oversight, and 503B outsourcing facilities prepare compounded drugs in advance of prescriptions under FDA cGMP oversight. Both channels require a prescription from a licensed provider and dispensing through a licensed pharmacy. The peptides themselves come from bulk drug substances that meet the regulatory criteria (FDA-approved, USP-monographed, or on the 503A bulks list).
The access landscape for compounded peptides is mid-shift. Tirzepatide and semaglutide compounding wound down in April-May 2025 after the shortage resolved. BPC-157, TB-500, CJC-1295, ipamorelin, thymosin alpha-1, and AOD-9604 are returning to compounding access through Q2-Q3 2026 per the HHS reclassification timeline. Sermorelin, NAD+, and a few longstanding compounded peptides remained available throughout the enforcement cycle. The clinics that operated continuously through 2023-2026 did so by working strictly within the 503A/503B framework, and those are the ones positioned to expand formularies as soon as the formal reinstatements publish.
The clinics below operate within the legitimate framework, have public physician oversight, and have been operating long enough to have established review histories. Each has a different specialty mix; we describe what they're known for rather than ranking them.
GobyMeds — telehealth focused on GLP-1s and wellness peptides through 503A/503B partnerships
Hone Health — initially testosterone-focused, now offers a broader peptide and longevity formulary
AgelessRx — longevity-focused telehealth offering NAD+, sermorelin, peptides, and prescription wellness compounds
Henry Meds — focused specifically on compounded GLP-1s for weight management with telehealth intake
Mochi Health — compounded GLP-1 focus with dietitian-led care model
Kingsberg Medical — HRT and peptide therapy clinic with established compounding pharmacy partnerships
Marek Health — functional medicine telehealth with peptide and hormone optimization protocols
The intake process across these platforms looks similar. A new patient submits a health history and goals through the website, often including recent lab work. A licensed provider reviews the intake, sometimes via video call (state requirements vary), and writes a prescription if clinically appropriate. The prescription is filled by the platform's compounding pharmacy partner and shipped to the patient. Follow-up consultations and refills happen through the platform.
Pricing varies by clinic and by peptide. Sermorelin runs $200-400 monthly. Compounded BPC-157 (when available again) tends to land at $150-300 monthly depending on dose. NAD+ injections run higher, often $300-500. Most platforms bundle the consultation fee into the first month's prescription cost.
Standard injection supplies
Bacteriostatic water, insulin syringes, and basic sterile-prep supplies aren't dispensed by every telehealth clinic, and even when they are, having a separate stock of supplies is convenient. The items below are commodity medical products available on Amazon and through pharmacy supply retailers.
Bacteriostatic water (0.9% benzyl alcohol preservative, 30 mL multi-dose vials) is the standard diluent for peptide reconstitution and the only diluent that gives reconstituted peptides their typical 2-6 week shelf life. Plain sterile water gives 24 hours. The branded versions from Hospira and similar pharmaceutical suppliers are interchangeable; vial size 30 mL is the practical default.
Insulin syringes are U-100 calibrated, 1 mL or 0.5 mL or 0.3 mL barrel, with permanent 30G or 31G needles. The 0.3 mL (30-unit) syringes give the best visual precision for sub-milligram doses. The 1 mL syringes accommodate larger draws but are harder to read at the low end. Buy 100-count or 200-count boxes; the per-syringe cost drops meaningfully at volume.
Alcohol prep pads (70% isopropyl, individually packaged, sterile) for vial-stopper and injection-site cleaning. Buy in 200-count or larger boxes. The branded medical-grade versions are functionally identical to the cheap generic boxes for this use case.
Sharps containers are FDA-approved puncture-resistant containers for used syringe disposal. The 1-quart and 2-quart sizes work well for personal use; municipal disposal rules vary by state, and most pharmacies accept full sharps containers for free disposal.
Sterile empty vials are useful for blending peptides (combining CJC-1295 with ipamorelin in a single vial, for example) or for storing aliquots when freezing portions for long-term stability. Look for borosilicate glass with rubber septum and aluminum crimp seal.
Peptide storage cases organize multiple reconstituted vials in a single refrigerated unit. Helpful when running 3-5 peptides simultaneously; not strictly necessary but convenient.
Bacteriostatic water — Amazon U-100 insulin syringes (1 mL, 0.5 mL, 0.3 mL options) — Amazon Alcohol prep pads (200-count) — Amazon Sharps container (1-quart) — Amazon Sterile empty vials — Amazon Peptide storage case — Amazon
Why this page doesn't list research peptide vendors
Six major research peptide vendors have closed in the past 18 months. Amino Asylum was raided by the FDA in June 2025. Paradigm Peptides pleaded guilty in a federal criminal case in December 2025. Science.bio shut down in January 2026. Peptide Sciences closed in March 2026 after independent testing reportedly found purity as low as 75% in their products. Canlab Research was suspended by Health Canada and the Supreme Court of Quebec.
State attorneys general have actively sued vendors selling research-grade GLP-1s direct to consumers. The Connecticut AG's May 2025 action established that "research grade" disclaimers don't insulate from state-level liability when marketing encourages human use. Forty-plus state AGs signed a letter to the FDA in late 2025 requesting joint federal-state enforcement on the channel.
The vendors that survived the enforcement cycle are operating with thinner margins, frequent regulatory pressure, and uncertain timelines. Some are credible; others aren't. Recommending specific vendors here would create three problems we'd rather avoid. Vendor stability is unpredictable: a vendor that's reliable today may close in 60 days. The legal posture risks state AG attention for the publisher (us) when the vendor's marketing crosses into human-use facilitation. And our publisher framing (research-tool publisher, not procurement guidance) gets weakened when a /vendors page reads as a buying guide.
Researchers conducting genuine in-vitro laboratory work on peptides should source from established academic suppliers like Bachem, Anaspec, Genscript, or Sigma-Aldrich, not from consumer-facing peptide retailers. Those suppliers ship to institutional addresses, sell at research-quantity scales, and provide the quality documentation laboratory work actually requires.
What to verify before any access channel
Per the editorial standards we apply across DrawDose, three things hold regardless of where a peptide came from.
A Certificate of Analysis from a third-party laboratory, with batch numbers tied to the specific lot. HPLC purity data and mass spectrometry identity confirmation. The COA tells you what's actually in the vial; the label tells you what should be.
The dispensing entity's licensure status. For FDA-approved drugs, this means a licensed pharmacy. For compounded drugs, this means a 503A pharmacy or 503B outsourcing facility under state board or FDA oversight. The licensure information should be publicly verifiable.
The provider's licensure status, if applicable. For prescribed compounds, the prescription must come from a provider licensed in your state. Telehealth platforms that prescribe across state lines maintain rosters of state-licensed providers; verify the platform handles your state before paying for an intake.
These checks are cheap. The downside risk of skipping them is meaningful.